MetaVia (MTVA) SEC Filings: History & Chart

MetaVia Inc.(MTVA)

Biotechnology · Cambridge, MA

$1.48-0.06 (-3.90%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About MetaVia Inc.

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Cambridge, MA

8 employees

www.metaviatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Hyung Heon Kim

View full financials

Form	Filing Date	Accepted	Document
8-K	May 27, 2026	May 27, 2026	View filing
8-K	May 18, 2026	May 18, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
10-Q	May 14, 2026	May 14, 2026	View filing
8-K	May 14, 2026	May 14, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
ARS	Apr 27, 2026	Apr 27, 2026	View filing
DEF 14A	Apr 27, 2026	Apr 27, 2026	View filing
PRE 14A	Apr 15, 2026	Apr 15, 2026	View filing
8-K	Apr 10, 2026	Apr 10, 2026	View filing
424B3	Apr 7, 2026	Apr 7, 2026	View filing
EFFECT	Apr 6, 2026	Apr 7, 2026	View filing
S-8	Apr 3, 2026	Apr 3, 2026	View filing
POS AM	Apr 3, 2026	Apr 3, 2026	View filing
8-K	Mar 26, 2026	Mar 26, 2026	View filing
10-K	Mar 26, 2026	Mar 26, 2026	View filing
8-K	Mar 26, 2026	Mar 26, 2026	View filing
8-K	Mar 18, 2026	Mar 18, 2026	View filing
4	Jan 27, 2026	Jan 27, 2026	View filing
8-K	Jan 27, 2026	Jan 27, 2026	View filing
4	Jan 27, 2026	Jan 27, 2026	View filing
8-K	Jan 16, 2026	Jan 16, 2026	View filing
424B4	Jan 16, 2026	Jan 16, 2026	View filing
EFFECT	Jan 15, 2026	Jan 16, 2026	View filing
S-1MEF	Jan 15, 2026	Jan 15, 2026	View filing
S-1/A	Jan 12, 2026	Jan 12, 2026	View filing
FWP	Jan 6, 2026	Jan 5, 2026	View filing
8-K	Jan 5, 2026	Jan 5, 2026	View filing
S-1	Jan 5, 2026	Jan 5, 2026	View filing
8-K	Jan 5, 2026	Jan 5, 2026	View filing

SEC Filings

Recent Filings